Optimizing outcomes in HCC: Comment on “optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis” by Jiang et al.

Recent years have witnessed notable advances in the management of intermediate and advanced hepatocellular carcinoma (HCC). However, several questions remain unanswered, including the timely transition from locoregional to systemic therapies and the lack of data on sequencing. In this Commentary, we...

Descripción completa

Detalles Bibliográficos
Autor principal: Rizzo, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523873/
https://www.ncbi.nlm.nih.gov/pubmed/34656968
http://dx.doi.org/10.1016/j.tranon.2021.101246
_version_ 1784585387382931456
author Rizzo, Alessandro
author_facet Rizzo, Alessandro
author_sort Rizzo, Alessandro
collection PubMed
description Recent years have witnessed notable advances in the management of intermediate and advanced hepatocellular carcinoma (HCC). However, several questions remain unanswered, including the timely transition from locoregional to systemic therapies and the lack of data on sequencing. In this Commentary, we critically discuss the results of the interesting meta-analysis conducted by Jiang and colleagues on the role of the combination therapy of trans-arterial chemoembolization (TACE) and sorafenib in this setting.
format Online
Article
Text
id pubmed-8523873
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-85238732021-10-25 Optimizing outcomes in HCC: Comment on “optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis” by Jiang et al. Rizzo, Alessandro Transl Oncol Commentary Recent years have witnessed notable advances in the management of intermediate and advanced hepatocellular carcinoma (HCC). However, several questions remain unanswered, including the timely transition from locoregional to systemic therapies and the lack of data on sequencing. In this Commentary, we critically discuss the results of the interesting meta-analysis conducted by Jiang and colleagues on the role of the combination therapy of trans-arterial chemoembolization (TACE) and sorafenib in this setting. Neoplasia Press 2021-10-14 /pmc/articles/PMC8523873/ /pubmed/34656968 http://dx.doi.org/10.1016/j.tranon.2021.101246 Text en © 2021 The Authors. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Commentary
Rizzo, Alessandro
Optimizing outcomes in HCC: Comment on “optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis” by Jiang et al.
title Optimizing outcomes in HCC: Comment on “optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis” by Jiang et al.
title_full Optimizing outcomes in HCC: Comment on “optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis” by Jiang et al.
title_fullStr Optimizing outcomes in HCC: Comment on “optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis” by Jiang et al.
title_full_unstemmed Optimizing outcomes in HCC: Comment on “optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis” by Jiang et al.
title_short Optimizing outcomes in HCC: Comment on “optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis” by Jiang et al.
title_sort optimizing outcomes in hcc: comment on “optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis” by jiang et al.
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523873/
https://www.ncbi.nlm.nih.gov/pubmed/34656968
http://dx.doi.org/10.1016/j.tranon.2021.101246
work_keys_str_mv AT rizzoalessandro optimizingoutcomesinhcccommentonoptimaltimingofcombiningsorafenibwithtransarterialchemoembolizationinpatientswithhepatocellularcarcinomaametaanalysisbyjiangetal

Ejemplares similares